A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA or Zoledronic Acid in Sweden, Denmark, and Norway

Trial Profile

A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA or Zoledronic Acid in Sweden, Denmark, and Norway

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid
  • Indications Cancer; Osteonecrosis
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 28 Mar 2016 Planned number of patients changed from 3600 to 2100 as per ClinicalTrials.gov record.
    • 28 Mar 2016 Planned End Date changed from 1 Dec 2019 to 1 Sep 2019 as per ClinicalTrials.gov record.
    • 29 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top